Jeremiah D Momper1, Brookie M Best1, Jiajia Wang2, Edmund V Capparelli1, Alice Stek3, Emily Barr4, Martina L Badell5, Edward P Acosta6, Murli Purswani7, Elizabeth Smith8, Nahida Chakhtoura9, Kyunghun Park1, Sandra Burchett10, David E Shapiro2, Mark Mirochnick11. 1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California. 2. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 3. University of Southern California School of Medicine, Los Angeles, California. 4. University of Colorado, Children's Hospital Colorado, Aurora, Colorado. 5. Emory University School of Medicine, Atlanta, Georgia. 6. University of Alabama at Birmingham, Birmingham, Alabama. 7. Bronx-Lebanon Hospital Center, Icahn School of Medicine at Mount Sinai, New York, New York. 8. Maternal, Adolescent, and Pediatric Research Branch, National Institute of Allergy and Infectious Diseases (NIAID). 9. Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland. 10. Children's Hospital Boston. 11. Boston University School of Medicine, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: To evaluate elvitegravir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery. DESIGN: Nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and their children in the United States. METHODS: Intensive steady-state 24-h pharmacokinetic profiles after 150 mg of elvitegravir and 150 mg of cobicistat given orally in fixed dose combination once-daily were performed during the second trimester, third trimester, and postpartum. Infant washout samples were collected after birth. Elvitegravir and cobicistat were measured in plasma by a validated liquid chromatography with tandem mass spectrometry assay with a lower quantitation limit of 10 ng/ml. A two-tailed Wilcoxon signed-rank test (α = 0.10) was employed for paired within-participant comparisons. RESULTS: Thirty pregnant women taking elvitegravir and cobicistat once-daily enrolled in the study. Compared with paired postpartum data, elvitegravir AUC0-24 was 24% lower in the second trimester [n = 14, P = 0.058, geometric mean ratios (GMR) = 0.76, 90% confidence interval (CI) 0.57-1.0] and 44% lower in the third trimester (n = 24, P = 0.0001, GMR = 0.56, 90% CI 0.42-0.73), while cobicistat AUC0-24 was 44% lower in the second trimester (n = 14, P = 0.0085, GMR = 0.56, 90% CI 0.37-0.85) and 59% lower in the third trimester (n = 24, P < 0.0001, GMR = 0.41, 90% CI 0.30-0.57). Median cord blood elvitegravir concentration was 540.6 ng/ml and the median ratio of cord blood to maternal plasma elvitegravir concentrations was 0.91. CONCLUSION: Standard elvitegravir and cobicistat dosing during pregnancy results in significantly lower exposure which may increase the risk of virologic failure and mother-to-child transmission. Additional studies are needed to optimize elvitegravir and cobicistat dosing regimens in pregnant women.
OBJECTIVE: To evaluate elvitegravir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery. DESIGN:Nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and their children in the United States. METHODS: Intensive steady-state 24-h pharmacokinetic profiles after 150 mg of elvitegravir and 150 mg of cobicistat given orally in fixed dose combination once-daily were performed during the second trimester, third trimester, and postpartum. Infant washout samples were collected after birth. Elvitegravir and cobicistat were measured in plasma by a validated liquid chromatography with tandem mass spectrometry assay with a lower quantitation limit of 10 ng/ml. A two-tailed Wilcoxon signed-rank test (α = 0.10) was employed for paired within-participant comparisons. RESULTS: Thirty pregnant women taking elvitegravir and cobicistat once-daily enrolled in the study. Compared with paired postpartum data, elvitegravir AUC0-24 was 24% lower in the second trimester [n = 14, P = 0.058, geometric mean ratios (GMR) = 0.76, 90% confidence interval (CI) 0.57-1.0] and 44% lower in the third trimester (n = 24, P = 0.0001, GMR = 0.56, 90% CI 0.42-0.73), while cobicistat AUC0-24 was 44% lower in the second trimester (n = 14, P = 0.0085, GMR = 0.56, 90% CI 0.37-0.85) and 59% lower in the third trimester (n = 24, P < 0.0001, GMR = 0.41, 90% CI 0.30-0.57). Median cord blood elvitegravir concentration was 540.6 ng/ml and the median ratio of cord blood to maternal plasma elvitegravir concentrations was 0.91. CONCLUSION: Standard elvitegravir and cobicistat dosing during pregnancy results in significantly lower exposure which may increase the risk of virologic failure and mother-to-child transmission. Additional studies are needed to optimize elvitegravir and cobicistat dosing regimens in pregnant women.
Authors: J Hakkola; H Raunio; R Purkunen; O Pelkonen; S Saarikoski; T Cresteil; M Pasanen Journal: Biochem Pharmacol Date: 1996-07-26 Impact factor: 5.858
Authors: Edwin DeJesus; Daniel Berger; Martin Markowitz; Calvin Cohen; Trevor Hawkins; Peter Ruane; Richard Elion; Charles Farthing; Lijie Zhong; Andrew K Cheng; Damian McColl; Brian P Kearney Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read Journal: AIDS Date: 2006-10-03 Impact factor: 4.177
Authors: Alice Stek; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Sandra K Burchett; Regis Kreitchmann; Kittipong Rungruengthanakit; Tim R Cressey; Lynne M Mofenson; Elizabeth Smith; David Shapiro; Mark Mirochnick Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731
Authors: Joseph M Custodio; Martin Rhee; Gong Shen; Kah Hiing J Ling; Brian P Kearney; Srinivasan Ramanathan Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191
Authors: Edward P Acosta; Arlene Bardeguez; Carmen D Zorrilla; Russell Van Dyke; Michael D Hughes; Sharon Huang; Lisa Pompeo; Alice M Stek; Jane Pitt; D Heather Watts; Elizabeth Smith; Eleanor Jiménez; Lynne Mofenson Journal: Antimicrob Agents Chemother Date: 2004-02 Impact factor: 5.191
Authors: Nikki Mulligan; Stein Schalkwijk; Brookie M Best; Angela Colbers; Jiajia Wang; Edmund V Capparelli; José Moltó; Alice M Stek; Graham Taylor; Elizabeth Smith; Carmen Hidalgo Tenorio; Nahida Chakhtoura; Marjo van Kasteren; Courtney V Fletcher; Mark Mirochnick; David Burger Journal: Front Pharmacol Date: 2016-08-04 Impact factor: 5.810
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Xiaomei I Liu; Jeremiah D Momper; Natella Rakhmanina; John N van den Anker; Dionna J Green; Gilbert J Burckart; Brookie M Best; Mark Mirochnick; Edmund V Capparelli; André Dallmann Journal: J Clin Pharmacol Date: 2019-09-06 Impact factor: 3.126
Authors: Diana F Clarke; Mark Mirochnick; Edward P Acosta; Edmund Capparelli; Anne Chain; Hedy Teppler; Betsy Smith; Jos Lommerse Journal: J Acquir Immune Defic Syndr Date: 2019-12-01 Impact factor: 3.731
Authors: Kristina M Brooks; Jeremiah D Momper; Mauricio Pinilla; Alice M Stek; Emily Barr; Adriana Weinberg; Jaime G Deville; Irma L Febo; Mikhaela Cielo; Kathleen George; Kayla Denson; Kittipong Rungruengthanakit; David E Shapiro; Elizabeth Smith; Nahida Chakhtoura; James F Rooney; Richard Haubrich; Rowena Espina; Edmund V Capparelli; Mark Mirochnick; Brookie M Best Journal: AIDS Date: 2021-03-01 Impact factor: 4.177
Authors: Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher Journal: Drugs Date: 2020-11 Impact factor: 9.546
Authors: Jeremiah D Momper; Jiajia Wang; Alice Stek; David E Shapiro; Gwendolyn B Scott; Mary E Paul; Irma L Febo; Sandra Burchett; Elizabeth Smith; Nahida Chakhtoura; Kayla Denson; Kittipong Rungruengthanakit; Kathleen George; Derek Z Yang; Edmund V Capparelli; Mark Mirochnick; Brookie M Best Journal: AIDS Date: 2021-07-01 Impact factor: 4.632